These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 16447221

  • 1. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
    Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, Schett G.
    Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
    [Abstract] [Full Text] [Related]

  • 2. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G.
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [Abstract] [Full Text] [Related]

  • 3. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.
    Cejka D, Hayer S, Niederreiter B, Sieghart W, Fuereder T, Zwerina J, Schett G.
    Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288
    [Abstract] [Full Text] [Related]

  • 4. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.
    Kumar S, Votta BJ, Rieman DJ, Badger AM, Gowen M, Lee JC.
    J Cell Physiol; 2001 Jun; 187(3):294-303. PubMed ID: 11319753
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
    Mbalaviele G, Anderson G, Jones A, De Ciechi P, Settle S, Mnich S, Thiede M, Abu-Amer Y, Portanova J, Monahan J.
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
    [Abstract] [Full Text] [Related]

  • 6. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis.
    Hayer S, Redlich K, Korb A, Hermann S, Smolen J, Schett G.
    Arthritis Rheum; 2007 Jan; 56(1):79-88. PubMed ID: 17195210
    [Abstract] [Full Text] [Related]

  • 7. The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss.
    Böhm C, Hayer S, Kilian A, Zaiss MM, Finger S, Hess A, Engelke K, Kollias G, Krönke G, Zwerina J, Schett G, David JP.
    J Immunol; 2009 Nov 01; 183(9):5938-47. PubMed ID: 19828631
    [Abstract] [Full Text] [Related]

  • 8. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
    Kang JS, Kim HM, Choi IY, Han SB, Yoon YD, Lee H, Park KH, Cho IJ, Lee CW, Lee K, Lee KH, Park SK.
    J Pharmacol Exp Ther; 2010 Aug 01; 334(2):657-64. PubMed ID: 20427474
    [Abstract] [Full Text] [Related]

  • 9. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
    Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA.
    J Pharmacol Exp Ther; 2006 Jul 01; 318(1):132-41. PubMed ID: 16597712
    [Abstract] [Full Text] [Related]

  • 10. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
    Binder NB, Puchner A, Niederreiter B, Hayer S, Leiss H, Blüml S, Kreindl R, Smolen JS, Redlich K.
    Arthritis Rheum; 2013 Mar 01; 65(3):608-17. PubMed ID: 23280418
    [Abstract] [Full Text] [Related]

  • 11. Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation.
    van Lent PL, Grevers L, Lubberts E, de Vries TJ, Nabbe KC, Verbeek S, Oppers B, Sloetjes A, Blom AB, van den Berg WB.
    Arthritis Rheum; 2006 Dec 01; 54(12):3868-77. PubMed ID: 17133594
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
    Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G.
    Arthritis Rheum; 2009 Sep 01; 60(9):2747-56. PubMed ID: 19714627
    [Abstract] [Full Text] [Related]

  • 13. JNK1 is not essential for TNF-mediated joint disease.
    Köller M, Hayer S, Redlich K, Ricci R, David JP, Steiner G, Smolen JS, Wagner EF, Schett G.
    Arthritis Res Ther; 2005 Sep 01; 7(1):R166-73. PubMed ID: 15642137
    [Abstract] [Full Text] [Related]

  • 14. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis.
    Saito H, Kojima T, Takahashi M, Horne WC, Baron R, Amagasa T, Ohya K, Aoki K.
    Arthritis Rheum; 2007 Apr 01; 56(4):1164-74. PubMed ID: 17393436
    [Abstract] [Full Text] [Related]

  • 15. Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs.
    Nieminen R, Korhonen R, Moilanen T, Clark AR, Moilanen E.
    Arthritis Rheum; 2010 Jun 01; 62(6):1650-9. PubMed ID: 20178133
    [Abstract] [Full Text] [Related]

  • 16. TNF-alpha mediates p38 MAP kinase activation and negatively regulates bone formation at the injured growth plate in rats.
    Zhou FH, Foster BK, Zhou XF, Cowin AJ, Xian CJ.
    J Bone Miner Res; 2006 Jul 01; 21(7):1075-88. PubMed ID: 16813528
    [Abstract] [Full Text] [Related]

  • 17. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo.
    Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S.
    Nat Med; 2004 Jun 01; 10(6):617-24. PubMed ID: 15156202
    [Abstract] [Full Text] [Related]

  • 18. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
    Konda VR, Desai A, Darland G, Bland JS, Tripp ML.
    Arthritis Rheum; 2010 Jun 01; 62(6):1683-92. PubMed ID: 20201075
    [Abstract] [Full Text] [Related]

  • 19. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, Keith RH, Li X, Mbalaviele G, Messing DM, Saabye MJ, Schindler JF, Selness SR, Stillwell LI, Webb EG, Zhang J, Monahan JB.
    J Pharmacol Exp Ther; 2009 Dec 01; 331(3):882-95. PubMed ID: 19720877
    [Abstract] [Full Text] [Related]

  • 20. The loss of α2β1 integrin suppresses joint inflammation and cartilage destruction in mouse models of rheumatoid arthritis.
    Peters MA, Wendholt D, Strietholt S, Frank S, Pundt N, Korb-Pap A, Joosten LA, van den Berg WB, Kollias G, Eckes B, Pap T.
    Arthritis Rheum; 2012 May 01; 64(5):1359-68. PubMed ID: 22083543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.